Exchange: NASDAQ·Updated 07:35 PM EDT

INCY News

News
all
press releases
Incyte to Report Third Quarter Financial Results
Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Thursday, October 29, 2026. The schedule for the press release and conference call/webcast is as follows: Q3 2026 Press Release: October 29, 2026, at 7:00...
Business Wire
Incyte to Report Third Quarter Financial Results
Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Thursday, October 29, 2026. The schedule for the press release and conference call/webcast is as follows: Q3 2026 Press Release: October 29, 2026, at 7:00...
Business Wire
More News
If You Invested $1000 In Incyte Stock 15 Years Ago, You Would Have This Much Today
Incyte (NASDAQ:INCY) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 14.45%. Currently, Incyte has a market capitalization of $22.70 billion.read more...
Benzinga
If You Invested $1000 In Incyte Stock 20 Years Ago, You Would Have This Much Today
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.48% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $23.82 billion.read more...
Benzinga
INCY or TECH: Which Is the Better Value Stock Right Now?
INCY vs. TECH: Which Stock Is the Better Value Option?
Zacks
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.
Zacks
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
Eli Lilly's Olumiant wins FDA nod to treat pediatric patients 12 years of age and older with severe alopecia areata, expanding its U.S. use after strong phase III results.
Zacks
MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary MiniMed appoints Sheila Denton as General Counsel & Corporate SecretaryPR NewswireNORTHRIDGE, Calif., Sept. 28, 2026 NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes...
PR Newswire
FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals
Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.
Stocktwits
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older...
Business Wire
INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill
The Food and Drug Administration’s target date is Saturday, September 26, for zilurgisertib, a once-daily pill for fibrodysplasia ossificans progressiva, or FOP, in patients 12 and older.
Stocktwits

Advertisement|Remove ads.